Corbus Pharmaceuticals Holdings, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $21.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-11
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $21.50M, a 8.90% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $23.60M, a 62.50% increase from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $14.52M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $21.50M 10-K · filed 2025-03-11 | |
| 2023-12-31 | $23.60M 10-K · filed 2025-03-11 | $23.56M 10-K · filed 2024-03-12 |
| 2022-12-31 | $14.52M 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |